practice. Introduction The coronavirus disease 2019 (COVID-19) has emerged in December 2019 in Wuhan, China, to quickly become a global outbreak and a significant public health issue [1, 2]. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern [3], and on March 20, 2020, due to the devastating number of new cases reported globally, WHO declared it as a pandemic [4]. At the time of drafting this manuscript (June 28, 2020), the WHO reported more than 9.5 million COVID-19 cases and 495,760 deaths [5]. During the pandemic, health care professionals (HCP) were faced with many challenges in the fight against an unprecedented and rapidly spreading disease [4]. This has prompted the WHO and the Centers for Disease Control and Prevention (CDC) to publish recommendations for the prevention and control of COVID-19 for HCP by the end of January 2020 In addition to disruptions due to the lockdown and the social distancing constraints [8, 9], the rheumatology practice had to face additional challenges. The medical community was uncertain if immunocompromised patients with rheumatic diseases had a higher risk of infection with the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) Several recommendations were developed worldwide to guide the rheumatologists in their therapeutic choices However, the decision to stop, pursue, or initiate therapies had to be determined, sometimes remotely, on a case-by-case basis, according to clinical judgment. In some cases, patients even decided to modify their treatment on their own without notifying their physician [23]. Moreover, some symptoms and signs may be overlapping between COVID-19 and immune-mediated disease flares [13, 15], which may cause diagnostic confusion in some cases and difficulties in making therapeutic decisions [24]. Furthermore, several rheumatology drugs were thought to have potential activity against the SARS-CoV-2, especially hydroxychloroquine (HCQ), thus leaving the rheumatology patients in drug shortage sometimes [25,26,27]. Finally, rheumatologists were regularly solicited by chronic patients for advice and by colleagues for assistance in rheumatology drugs prescription for COVID-19 cytokine storm management [28, 29], which could be mentally draining. Therefore, COVID-19 pandemic is a truly challenging time for rheumatologists, particularly in the Arab countries. Unlike the USA or Western Europe [30, 31], the concept of telemedicine is not well established in the Arab world. The main obstacles include the absence of a legal telemedicine framework and the reluctance of patients to renounce their privileged physician-patient direct communication. For this purpose, rheumatologists from the Arab League of Associations for Rheumatology (ArLAR) designed a survey to evaluate the difficulties faced by the rheumatologists in the Arab countries. Objectives The primary objective was to evaluate the impact of COVID-19 pandemic on rheumatology practice in the Arab countries. The secondary objectives were to evaluate the impact of COVID-19 on the rheumatologists themselves and to develop suggestions to improve the rheumatology practice in the region. Method A 21-item web-based, cross-sectional survey was developed by a steering committee comprising rheumatologists from the ArLAR. The survey was designed in English, based on the available literature, and following the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) guidelines [32]. It was validated by the ArLAR scientific committee, which consists of rheumatologists representing all 15 ArLAR countries. The